Visit http://indiaer.blogspot.com/ for complete details Ranbaxy (Rating – Under Review)
We expect the company to report net sales of Rs18.7bn.
We expect a 320bps increase on a YoY basis in the EBIDTA margin to 16.1% owing to higher
sales from high margin formulations exports.
Adjusted PAT is expected to grow by 42% to Rs1.9bn.
No comments:
Post a Comment